Southwestern Internal Medicine Conference: Bone disease in kidney failure: Diagnosis and management

R. E. Cronin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Recent technologic and therapeutic advances have improved the life of the patient with end-stage renal disease. High efficiency and high-flux hemodialyzer membranes have shortened the time required to dialyze, and recombinant erythropoietin has all but eliminated anemia as a major cause of morbidity, but the problem of renal osteodystrophy remains. The following discussion examines the spectrum of bone and joint disease in the patient with end-stage renal disease. The diagnostic and therapeutic strategies currently being tried in the management of these disorders are discussed.

Original languageEnglish (US)
Pages (from-to)192-205
Number of pages14
JournalAmerican Journal of the Medical Sciences
Volume306
Issue number3
StatePublished - 1993

Fingerprint

Bone Diseases
Internal Medicine
Chronic Kidney Failure
Renal Insufficiency
Artificial Kidneys
Chronic Kidney Disease-Mineral and Bone Disorder
Joint Diseases
Erythropoietin
Anemia
Morbidity
Membranes
Therapeutics

Keywords

  • Aluminum-induced osteomalacia
  • Calcitriol
  • Deferoximine
  • Hemodialysis-related amyloidosis
  • Parathyroidectomy
  • Renal osteodystrophy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Southwestern Internal Medicine Conference : Bone disease in kidney failure: Diagnosis and management. / Cronin, R. E.

In: American Journal of the Medical Sciences, Vol. 306, No. 3, 1993, p. 192-205.

Research output: Contribution to journalArticle

@article{375e6b7e20e84796a759ba91be8c1d8f,
title = "Southwestern Internal Medicine Conference: Bone disease in kidney failure: Diagnosis and management",
abstract = "Recent technologic and therapeutic advances have improved the life of the patient with end-stage renal disease. High efficiency and high-flux hemodialyzer membranes have shortened the time required to dialyze, and recombinant erythropoietin has all but eliminated anemia as a major cause of morbidity, but the problem of renal osteodystrophy remains. The following discussion examines the spectrum of bone and joint disease in the patient with end-stage renal disease. The diagnostic and therapeutic strategies currently being tried in the management of these disorders are discussed.",
keywords = "Aluminum-induced osteomalacia, Calcitriol, Deferoximine, Hemodialysis-related amyloidosis, Parathyroidectomy, Renal osteodystrophy",
author = "Cronin, {R. E.}",
year = "1993",
language = "English (US)",
volume = "306",
pages = "192--205",
journal = "The American journal of the medical sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Southwestern Internal Medicine Conference

T2 - Bone disease in kidney failure: Diagnosis and management

AU - Cronin, R. E.

PY - 1993

Y1 - 1993

N2 - Recent technologic and therapeutic advances have improved the life of the patient with end-stage renal disease. High efficiency and high-flux hemodialyzer membranes have shortened the time required to dialyze, and recombinant erythropoietin has all but eliminated anemia as a major cause of morbidity, but the problem of renal osteodystrophy remains. The following discussion examines the spectrum of bone and joint disease in the patient with end-stage renal disease. The diagnostic and therapeutic strategies currently being tried in the management of these disorders are discussed.

AB - Recent technologic and therapeutic advances have improved the life of the patient with end-stage renal disease. High efficiency and high-flux hemodialyzer membranes have shortened the time required to dialyze, and recombinant erythropoietin has all but eliminated anemia as a major cause of morbidity, but the problem of renal osteodystrophy remains. The following discussion examines the spectrum of bone and joint disease in the patient with end-stage renal disease. The diagnostic and therapeutic strategies currently being tried in the management of these disorders are discussed.

KW - Aluminum-induced osteomalacia

KW - Calcitriol

KW - Deferoximine

KW - Hemodialysis-related amyloidosis

KW - Parathyroidectomy

KW - Renal osteodystrophy

UR - http://www.scopus.com/inward/record.url?scp=0027371505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027371505&partnerID=8YFLogxK

M3 - Article

C2 - 8128983

AN - SCOPUS:0027371505

VL - 306

SP - 192

EP - 205

JO - The American journal of the medical sciences

JF - The American journal of the medical sciences

SN - 0002-9629

IS - 3

ER -